- Home
- BCTXZ vs MLNK Comparison
BCTXZ vs MLNK Comparison
Compare BCTXZ & MLNK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTXZ
- MLNK
- Stock Information
- Founded
- BCTXZ N/A
- MLNK 1998
- Country
- BCTXZ Canada
- MLNK United States
- Employees
- BCTXZ 12
- MLNK N/A
- Industry
- BCTXZ
- MLNK Computer Software: Prepackaged Software
- Sector
- BCTXZ
- MLNK Technology
- Exchange
- BCTXZ Nasdaq
- MLNK Nasdaq
- Market Cap
- BCTXZ N/A
- MLNK N/A
- IPO Year
- BCTXZ N/A
- MLNK 2021
- Fundamental
- Price
- BCTXZ $0.94
- MLNK $17.41
- Analyst Decision
- BCTXZ
- MLNK Hold
- Analyst Count
- BCTXZ 0
- MLNK 7
- Target Price
- BCTXZ N/A
- MLNK $21.21
- AVG Volume (30 Days)
- BCTXZ N/A
- MLNK 180.1K
- Earning Date
- BCTXZ N/A
- MLNK 05-12-2025
- Dividend Yield
- BCTXZ N/A
- MLNK N/A
- EPS Growth
- BCTXZ N/A
- MLNK N/A
- EPS
- BCTXZ N/A
- MLNK N/A
- Revenue
- BCTXZ N/A
- MLNK $316,298,000.00
- Revenue This Year
- BCTXZ N/A
- MLNK $6.07
- Revenue Next Year
- BCTXZ N/A
- MLNK $5.81
- P/E Ratio
- BCTXZ N/A
- MLNK N/A
- Revenue Growth
- BCTXZ N/A
- MLNK 4.18
- 52 Week Low
- BCTXZ N/A
- MLNK $15.57
- 52 Week High
- BCTXZ N/A
- MLNK $25.33
- Technical
- Relative Strength Index (RSI)
- BCTXZ N/A
- MLNK 55.35
- Support Level
- BCTXZ N/A
- MLNK $16.16
- Resistance Level
- BCTXZ N/A
- MLNK $16.93
- Average True Range (ATR)
- BCTXZ 0.00
- MLNK 0.39
- MACD
- BCTXZ 0.00
- MLNK 0.17
- Stochastic Oscillator
- BCTXZ 0.00
- MLNK 93.81
About BCTXZ BriaCell Therapeutics Corp. Warrant
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.